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Abstract 
Background: Reports are conflicting on whether serum uric acid (sUA) levels are 
independently associated with increased cardiovascular (CV) death risk.  
Methods: This post hoc analysis assessed the relationship between sUA levels and 
CV death risk score in 7531 patients from the cross-sectional, multinational EURIKA 
study (NCT00882336). Patients had at least one CV risk factor but no clinical CV 
disease. Ten-year risk of CV death was estimated using SCORE-HDL and SCORE 
algorithms, categorized as low (< 1%), intermediate (1% to < 5%), high (≥ 5% to 
< 10%) or very high (≥ 10%). 
Results: Mean serum sUA levels increased significantly with increasing CV death 
risk category in the overall population and in subgroups stratified by diuretics use or 
renal function (all P < 0.0001). Multivariate ordinal logistic regression analyses, 
adjusted for factors significantly associated with CV death risk in univariate analyses 
(study country, body mass index, number of CV risk factors and comorbidities, use of 
lipid lowering therapies, antihypertensives and antidiabetics), showed a significant 
association between sUA levels and SCORE-HDL category in the overall population 
(OR: 1.39 [95% CI: 1.34–1.44]) and all subgroups (using diuretics: 1.32 [1.24–1.40]; 
not using diuretics: 1.46 [1.39–1.53]; estimated glomerular filtration rate [eGFR] 
< 60 ml/min/1.73 m
2
: 1.30 [1.22–1.38]; eGFR ≥ 60 ml/min/1.73 m2: 1.44 [1.38–1.51]; 
all P < 0.0001). Similar results were obtained when using SCORE. 
Conclusions: Higher sUA levels are associated with progressively higher 10-year CV 
death risk score in patients with at least one CV risk factor but no CV disease. 
 
Word count: 250 words 
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Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; 
EURIKA, European Study on Cardiovascular Risk Prevention and Management in 
Usual Daily Practice; HDL, high-density lipoprotein; SCORE, Systematic COronary 
Risk Evaluation; SD, standard deviation; sUA, serum uric acid. 
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1. Introduction 
Uric acid, the waste product of purine metabolism, has protective antioxidant 
properties, but has also been described as a mediator of pathological processes, 
including inflammation and endothelial dysfunction [1, 2]. Increasing levels of serum 
uric acid (sUA) have been implicated in the pathophysiology of cardiovascular (CV) 
and cardiorenal conditions, such as hypertension [3-5], diabetes [6, 7], metabolic 
syndrome [5, 8, 9], coronary artery disease [10] and kidney disease [5, 11, 12]. 
There is much debate around whether an independent association exists 
between sUA levels and increased risk of CV death. Several studies have reported an 
independent association [13-15], but others have been unable to confirm such a 
relationship [16-19]. Data from the first National Health and Nutrition Examination 
Survey (NHANES) Epidemiologic Follow-up Study suggested that sUA levels were 
independently associated with CV death regardless of diuretics use and sex [13]. 
Diuretics use and estimated glomerular filtration rate (eGFR) were reported as key 
confounders in the Framingham Heart Study and a study based on data from the 
NHANES, respectively [16, 18]. However, since both factors might raise sUA levels 
without contemporarily affecting CV risk, they must be considered as factors that can 
prevent the identification of a true increased CV risk and not as confounders that 
support the lack of a relationship. In the Framingham Heart Study, levels of sUA were 
associated with an increased risk of CV death in women but not in men, and the 
association disappeared after adjustment for well-known CV risk factors. Adjustment 
for potential confounders needs to be performed with care, however, because it may 
adjust inappropriately for factors such as blood pressure that have a direct, causal 
relationship with sUA rather than being markers of confounding [16]. 
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The European Study on CV Risk Prevention and Management in Usual Daily 
Practice (EURIKA; ClinicalTrials.gov Identifier: NCT00882336) was conducted to 
assess clinical practice in the primary prevention of CV disease across Europe [20]. 
EURIKA included individuals from 12 European countries with at least one CV risk 
factor but no clinical CV disease and was performed mostly in the primary 
prevention, primary care setting, where hyperuricaemia is commonly managed by 
clinicians. This is in contrast with previously conducted studies, which were mostly 
population-based surveys [13, 14, 18] or conducted in the clinical trial setting [17], 
recruited North American individuals [13, 14, 16, 18] or were centred on predicting 
the effect of genetic scores [15]. The aim of the current, post hoc analysis was to 
assess the association between sUA levels and the estimated 10-year risk of CV death 
in patients in EURIKA, evaluated using a CV death risk score algorithm. The 
potential specific associations of sUA levels with hypertension and diabetes were also 
explored. 
 
2. Methods 
2.1. Study design and participants 
EURIKA was conducted in 12 European countries (Austria, Belgium, France, 
Germany, Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey, and the UK) 
[21]. Data were collected between May 2009 and January 2010, with a 3-month data 
collection period for each country. The methods for the study have been reported in 
detail elsewhere [20]. In brief, the study sample was selected in a two-step process 
that involved recruitment of physicians and their patients [20, 22]. In the first stage, a 
sample of approximately 60 physicians involved in CV disease prevention (primary 
care physicians and specialists) was randomly selected from each country using the 
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Cegedim OneKey database (www.cegedim.com). A total of 809 physicians agreed to 
participate in EURIKA, 64% of whom were primary care physicians [22]. 
In the second stage, participating physicians invited patients who were aged 
50 years or older, were free from CV disease and had at least one of the following five 
major CV disease risk factors: 1) dyslipidaemia, defined as high levels of low-density 
lipoprotein cholesterol (LDL-C; ≥ 4.1 mmol/L [≥ 160 mg/dl]) or low levels of high-
density lipoprotein cholesterol (HDL-C; < 1.036 mmol/L [< 40 mg/dl] for men, 
< 1.300 mmol/L [< 50 mg/dl] for women) or high triglyceride levels (≥ 1.7 mmol/L 
[≥ 150 mg/dl]) or receiving lipid-lowering medication; 2) hypertension, defined as a 
systolic blood pressure of at least 140 mmHg or a diastolic blood pressure of at 
least 90 mmHg or receiving antihypertensive medication; 3) smoking, defined as 
being a current or former smoker with more than 100 cigarettes smoked in their 
lifetime; 4) diabetes mellitus, defined as a fasting plasma glucose level of at least 
7.0 mmol/L (126 mg/dl), or receiving insulin or oral antidiabetic medication; 5) 
obesity, defined as a body mass index (BMI) of at least 30 kg/m
2
, or a waist 
circumference of at least 102 cm in men and at least 88 cm in women. 
Approximately 600 patients were included per country, with a total population 
size of 7641 in EURIKA [21]. The current analysis includes only patients for whom 
information on sUA levels was available (N = 7531). 
The study protocol was approved by the appropriate clinical research ethics 
committees in each participating country, and all patients provided signed informed 
consent before enrolment. 
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2.2. Baseline characteristics and clinical measurements 
The demographic details and medical history of participating patients were 
gathered from medical records and patient interviews. For each patient, a physical 
examination was conducted, blood pressure was measured and a 12-h fasting blood 
sample was collected within 1 day of the initial outpatient consultation. Blood 
pressure measurements were obtained under standardized conditions, using calibrated 
mercury sphygmomanometers or validated automated devices, and appropriate-size 
cuffs. The mean of three consecutive measurements in the sitting position and spaced 
1–2 min apart was used for the analyses [23]. The blood sample analysis was 
performed by a central laboratory (Bio Analytical Research Corporation, Ghent, 
Belgium), with the exception of patients in Russia (approximately 5% of all patients), 
for whom laboratory analysis was conducted locally. All participating physicians 
were asked in the clinical report form to provide enrolled patients’ eGFR in 
ml/min/1.73 m
2
. 
 
2.3. Systematic coronary risk evaluation  
Patients’ 10-year risk of CV death was estimated using the Systematic 
COronary Risk Evaluation (SCORE) [24] and SCORE-HDL [25] algorithms. 
SCORE-HDL is an updated version of the SCORE algorithm that takes into account 
total cholesterol and HDL-C levels as independent variables. Algorithms developed 
for low-risk regions were used for patients in Belgium, France, Greece, Spain and 
Switzerland, and algorithms for high-risk regions were utilized for patients in Austria, 
Germany, Norway, Russia, Sweden, Turkey and the UK [24, 25].  
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2.4. Statistical analyses 
Statistical analyses were carried out using SAS (V9.2, SAS Institute Inc., 
Cary, NC, USA). SCORE-HDL and SCORE were analyzed as categorical variables 
using four score categories: low (< 1%); intermediate (≥ 1% to < 5%); high (≥ 5% to 
< 10%); and very high (≥ 10%). Univariate analyses were conducted to compare 
explanatory variables across the four SCORE-HDL or SCORE categories, using 
analysis of variance (ANOVA) for continuous explanatory variables and chi-square 
test for categorical explanatory variables. Explanatory variables assessed were: blood 
uric acid concentration; BMI; study country; number of CV risk factors (1 to 5); 
number of comorbidities (0 to ≥ 4); use of lipid-lowering drug (at least one type 
versus no); use of antihypertensive drug (at least one type versus no); and use of 
antidiabetic drug (at least one type versus no). Multivariate analyses were conducted 
using an ordinal logistic regression model, to explore the potential association of 
higher 10-year risk of CV death category with increasing sUA levels and explanatory 
variables. Each variable was adjusted for all other variables in the explanatory model 
shown to be significantly related (P < 0.1) to risk score of CV death in the univariate 
analysis, and for study country and BMI as potential confounders. To validate the use 
of the ordinal logistic regression model, three binary logistic models were first fitted 
(risk score < 1% versus ≥ 1%, < 5% versus ≥ 5%, and < 10% versus ≥ 10%) to 
confirm that odds ratios (ORs) between adjacent risk categories were of the same 
magnitude.  
Analyses were conducted in the overall population, and in subgroups stratified 
by the absence or presence of renal dysfunction according to eGFR (eGFR 
≥ 60 ml/min/1.73 m2 versus eGFR < 60 ml/min/1.73 m2, respectively), or by diuretics 
use (yes versus no). In addition, multivariate analyses were utilized to model the 
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likelihood of having hypertension or diabetes by sUA levels in the overall population, 
with ORs calculated for an increase of 1 mg/dl of sUA. The sUA cut-off value at 
which the likelihood of having hypertension or diabetes was increased was chosen to 
maximize the Youden index.  
 
3. Results 
3.1. Patient demographics and baseline characteristics 
Demographic and clinical characteristics of the 7531 included patients are 
listed in Table 1, overall and by diuretics use and eGFR. The mean age of participants 
was 63.2 years (standard deviation [SD]: 9.0) and 51.7% were women. The mean 
concentration of sUA was 5.2 mg/dl (SD: 1.4), with 26.6% of patients having sUA 
concentrations above 6 mg/dl. In terms of CV disease risk factor distribution, the 
proportion of patients with one, two, three, four or five major risk factors was 21.5%, 
31.9%, 27.3%, 15.0% and 4.3%, respectively. Overall, 23.6% of patients were 
classified as being at high or very high 10-year risk of CV death using the SCORE-
HDL algorithm; the proportion was 41.0% when using the SCORE algorithm.  
A total of 2214 individuals (29.4%) had an eGFR below 60 ml/min/1.73 m
2
 
and 2356 participants (31.3%) were receiving diuretics treatment. The proportion of 
individuals at high or very high 10-year risk of CV death was greater in patients using 
diuretics than in patients not using diuretics (Table 1). 
The countries with the highest proportions of study patients with high or very 
high risk of CV death were Austria, Germany, Norway, Sweden and the UK, both 
when using SCORE-HDL (33.4%, 40.9%, 39.0%, 41.9% and 36.1%, respectively) 
and when using SCORE (44.2%, 59.5%, 52.8%, 58.7% and 54.2%, respectively). The 
countries with the lowest proportions of study patients with high or very high risk of 
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CV death when using SCORE-HDL were Belgium, France and Spain (4.1%, 6.1%, 
6.2%, respectively), and when using SCORE were Greece, Russia and Spain (27.1%, 
29.3% and 29.7%, respectively).  
 
3.2. Relationship between sUA levels and risk of cardiovascular death  
Mean serum sUA levels increased with increasing SCORE-HDL risk category 
in the overall study population, as well as in the four subgroups stratified by diuretics 
use or by renal function according to eGFR (all P < 0.0001) (Fig. 1). Similar results 
were obtained when using SCORE (Fig. 2).  
The following factors were significantly related to SCORE-HDL and SCORE 
in the univariate analysis and were adjusted for in the multivariate ordinal logistic 
regression analyses for SCORE-HDL and SCORE: study country; BMI; number of 
CV risk factors; number of comorbidities (except for SCORE-HDL in the subgroup 
using diuretics, for which no significant relationship was observed in the univariate 
analysis); use of lipid lowering drugs; use of antihypertensive drugs (except for the 
subgroup of patients using diuretics, who were all using antihypertensive drugs); and 
use of antidiabetic drugs.  
Multivariate analyses using ordinal logistic regression (SCORE-HDL or 
SCORE category: low; intermediate; high; or very high) showed significant 
associations between increasing mean sUA levels and increasing SCORE-HDL or 
SCORE risk category: using SCORE-HDL, the odds ratio (OR) (95% CI) was 1.39 
(1.34–1.44) in the overall population, 1.32 (1.24–1.40) in patients using diuretics, 
1.46 (1.39–1.53) in those not using diuretics, 1.30 (1.22–1.38) in patients with an 
eGFR below 60 ml/min/1.73 m
2
, and 1.44 (1.38–1.51) in those with an eGFR of 
60 ml/min/1.73 m
2
 and above (all P < 0.0001) (Table 2). Using SCORE, the 
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corresponding values were 1.29 (1.25–1.33), 1.22 (1.15–1.28), 1.33 (1.28–1.39), 1.23 
(1.16–1.30), and 1.27 (1.22–1.33) (all P < 0.0001) (Table S1). 
Other variables identified as having a significant, positive association with CV 
death risk in the overall population were increasing number of CV risk factors, 
increasing number of comorbidities, and use of lipid-lowering and antihypertensive 
drugs (likely to be proxies of CV risk factors/comorbidities, i.e. confounding by 
indication), but not use of antidiabetic drugs (Table 2 [SCORE-HDL], Table S1 
[SCORE]). Study country was a factor independently and significantly associated 
with CV death risk in the current model (results not shown). Tying in with the 
“obesity paradox” in CV disease, BMI had a significant, negative (i.e. protective) 
effect on CV death risk.  
 
3.3. Relationship between sUA levels, hypertension and diabetes 
sUA levels were significantly higher in patients with hypertension (mean: 5.4; 
SD: 1.4) than in those without hypertension (mean: 4.8; SD: 1.2) (P < 0.0001), and in 
patients with diabetes (mean: 5.4; SD: 1.5) than without diabetes (mean: 5.2; SD: 1.4) 
(P < 0.0001). On multivariate analysis, a significant association was observed 
between sUA levels and risk of hypertension (OR: 1.36; 95% CI: 1.30–1.43; P 
< 0.0001), but not between sUA levels and risk of diabetes (OR: 0.98; 95% CI: 0.94–
1.03; P = 0.4025). The sUA cut-off value that determined an increased likelihood of 
having hypertension was 5.3 mg/dl (sensitivity: 49%; specificity: 69%; area under the 
receiver operating characteristic curve: 0.6232). 
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4. Discussion 
This post hoc analysis was designed to determine the association between sUA 
levels and estimated risk of CV death in patients with at least one CV risk factor but 
with no clinical CV disease. Results of the analysis demonstrate a significant, positive 
association between sUA levels and high scores for risk of 10-year CV death. The 
association remained significant when adjusting for potential confounders (study 
country and any factors that were identified as being significantly associated with 
increased risk of CV death in the univariate analysis). Our results suggest a key role 
for sUA in CV disease. Causality cannot be inferred from this cross-sectional study. 
However, if verified, then monitoring sUA levels could in future be considered as part 
of primary CV disease prevention in at-risk patients. 
The association between sUA levels and increased risk score for CV death was 
found in individuals with renal dysfunction (assessed via eGFR) and in those using 
diuretics, but also in patients without renal dysfunction and in those not taking 
diuretic drugs. These observations support a primary role for sUA production rather 
than sUA excretion in CV disease risk and have important implications regarding the 
mechanism of sUA involvement in CV disease. 
The 2016 European guidelines recommend using the SCORE algorithm to 
estimate risk of CV death in apparently healthy adults without CV disease. The 
algorithm estimates the 10-year risk of CV death and has been calibrated for low-risk 
and high-risk regions based on country-specific mortality rates [24, 25]. The pattern 
of risk factors, control of risk factors and SCORE risk in our study population are 
similar to the distributions described for similar ‘real world’ populations in the 
SCORE algorithm publications [24, 25]. The original SCORE algorithm was recently 
updated to include HDL-C as well as total cholesterol, systolic blood pressure, age, 
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sex and smoking status [26, 27]. Use of the SCORE-HDL algorithm tends to result in 
reclassification from higher to lower risk categories when compared with the SCORE 
algorithm [26]. In the current study, 41.1% of patients were classified as being at high 
10-year risk of CV death based on SCORE, compared with 23.6% when using 
SCORE-HDL. The significant association observed between sUA and increased risk 
of CV death in the current analysis was found both when using SCORE and when 
using SCORE-HDL to calculate risk. To explore whether inclusion of sUA levels 
would add additional, relevant information to existing CV disease risk scores, a cohort 
study (either secondary data from an existing study or a new cohort study) is 
needed to model the risk of CV events, with SCORE (or SCORE-HDL) and sUA as 
variables in the model. Furthermore, future risk models need not be restricted  
just to using existing CV disease risk scores as variables; should sUA be seen to 
be an independent predictor, a model updating process should come into place 
(for example, it cannot be ruled out that sUA replaces one of the existing factors). 
More than a quarter (26.6%) of adults in EURIKA had sUA concentrations 
above 6 mg/dl. This is only slightly lower than the prevalence in the USA, which was 
found to be 32.8% in a study based on data from the NHANES [28]. In contrast, a 
population-based study conducted in Italy observed a much lower prevalence for sUA 
concentrations above 6 mg/dl, at 8.5% and 11.9% in 2005 and 2009, respectively [29]. 
Reference ranges for sUA values tend to be based on levels measured in the general 
population, but a causal role of sUA in CV disease suggests that aiming for lower than 
average population values may be more appropriate [30]. In the current study, the 
mean concentration of sUA was 5.2 mg/dl, which is similar to the mean of 5.5 mg/dl 
observed in the NHANES studies [13, 28]. Mean sUA levels were significantly higher 
in patients with hypertension than in those without hypertension. Levels of 5.3 mg/dl 
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or above determined an increased likelihood of having hypertension in the current 
analysis, supporting the suggestion that the definition of the normal range of sUA 
levels may need to be revised [30].  
Strengths of EURIKA include the use of standardized procedures to collect 
data and of a central laboratory for blood analyses. A limitation of the current analysis 
is that EURIKA included only a single measurement of sUA levels. Furthermore, the 
cross-sectional design of EURIKA means that the study does not provide insight into 
the longitudinal association between sUA levels and the development of CV disease. 
The presence of gout and use of gout-controller medications were not captured in 
EURIKA, and any associations of gout and treatment with CV disease risk could thus 
not be analyzed. Results were not analyzed by sex. A potential limitation of the 
current analysis is that both SCORE and SCORE-HDL are recommended for use in 
individuals aged 40–65 years, whereas an important proportion of the current study 
population will have been older than 65 years. Of note, for SCORE, the age is 
multiplied by a unique coefficient, whatever the age. However, for SCORE-HDL, the 
same coefficient as for 65-year-olds was applied to individuals older than 65 years, 
which will probably have resulted in an underestimation rather than an overestimation 
of the association between sUA levels and CV disease risk in the older patient group. 
Although it is unlikely that the association between sUA levels and SCORE or 
SCORE-HDL risk category in this population with no clinical CV disease could be 
explained entirely by an association of sUA levels with one of the variables included 
in SCORE or SCORE-HDL, this possibility cannot be ruled out entirely. Finally, the 
possibility that residual confounding factors may explain the association between sUA 
and SCORE is not excluded. 
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In conclusion, results of this analysis demonstrate that sUA levels are 
significantly, positively associated with a score for 10-year risk of CV death in 
patients with at least one CV risk factor but with no clinical CV disease. Prospective 
cohort studies are needed to establish causality and model the observed risk of CV 
events, with SCORE-HDL (and/or SCORE) and sUA levels as variables, to explore 
whether the inclusion of sUA levels would add additional, relevant information to 
existing CV disease risk scores. 
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Table 1 
Demographic and clinical characteristics of patients in EURIKA with sUA data, by diuretics use and eGFR. 
 Overall 
(N = 7531) 
Using diuretics 
(n = 2356) 
Not using 
diuretics 
(n = 5175) 
eGFR 
< 60 ml/min/1.73m
2
 
(n = 2214
*
) 
eGFR 
≥ 60 ml/min/1.73m2 
(n = 5309
*
) 
Age, years 63.2 (9.0) 65.4 (9.0) 62.1 (8.7) 66.6 (9.4) 61.7 (8.4) 
Women, n (%) 3897 (51.7) 1289 (54.7) 2608 (50.4) 1329 (60.0) 2565 (48.3) 
BMI, kg/m
2
 28.9 (5.4) 30.2 (5.7) 28.4 (5.2) 29.1 (5.5) 28.9 (5.4) 
Hypertension, n (%) 5466 (72.6) 2356 (100.0) 3110 (60.1) 1757 (79.4) 3702 (69.7) 
Dyslipidaemia, n (%) 4360 (57.9) 1417 (60.1) 2943 (56.9) 1359 (61.4) 2997 (56.5) 
Type 2 diabetes, n (%) 2016 (26.8) 756 (32.1) 1260 (24.3) 546 (24.7) 1468 (27.7) 
Obesity, n (%) 3273 (43.5) 1257 (53.4) 2016 (39.0) 987 (44.6) 2282 (43.0) 
Current or former smokers, 
n (%) 
3601 (47.8) 979 (41.6) 2622 (50.7) 938 (42.4) 2658 (50.1) 
sUA, mg/dl 5.2 (1.4) 5.7 (1.5) 5.0 (1.3) 5.6 (1.5) 5.1 (1.3) 
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 ≤ 6 mg/dl, n (%) 5524 (73.4) 1443 (61.2) 4081 (78.9) 1461 (66.0) 4059 (76.5) 
 > 6 mg/dl, n (%) 2007 (26.6) 913 (38.8) 1094 (21.1) 753 (34.0) 1250 (23.5) 
SCORE-HDL, % 3.6 (3.2) 4.0 (3.3) 3.5 (3.1) 3.7 (3.0) 3.6 (3.2) 
 < 1%, n (%) 1137 (15.3) 229 (9.8) 908 (17.8) 293 (13.4) 843 (16.1) 
 1 to < 5%, n (%) 4528 (61.0) 1469 (63.0) 3059 (60.1) 1366 (62.4) 3157 (60.4) 
 ≥ 5% to < 10%, n (%) 1427 (19.2) 501 (21.5) 926 (18.2) 448 (20.5) 977 (18.7) 
 ≥ 10%, n (%) 328 (4.4) 131 (5.6) 197 (3.9) 81 (3.7) 247 (4.7) 
 Unknown, n (%) 111 (1.5) 26 (1.1) 85 (1.6) 26 (1.2) 85 (1.6) 
SCORE, % 6.0 (6.3) 7.0 (6.8) 5.5 (6.0) 7.1 (7.0) 5.5 (5.9) 
 < 1%, n (%) 868 (11.7) 159 (6.8) 709 (13.9) 189 (8.6) 679 (13.0) 
 1% to < 5%, n (%) 3507 (47.3) 1023 (43.9) 2484 (48.8) 914 (41.7) 2587 (49.5) 
 ≥ 5% to < 10%, n (%) 1790 (24.1) 638 (27.4) 1152 (22.6) 593 (27.1) 1196 (22.9) 
 ≥ 10%, n (%) 1257 (16.9) 510 (21.9) 747 (14.7) 494 (22.6) 762 (14.6) 
 Unknown, n (%) 109 (1.4) 26 (1.1) 83 (1.6) 24 (1.1) 85 (1.6) 
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BMI: body mass index, eGFR: estimated glomerular filtration rate, HDL: high-density lipoprotein, SCORE: Systematic COronary Risk 
Evaluation, SD: standard deviation, sUA: serum uric acid. 
*
Data on eGFR missing for eight patients. 
Data are mean (SD) unless otherwise stated.
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Table 2 
Multivariate ordinal logistic regression analysis to model the association of sUA and other patient variables with SCORE-HDL in the overall 
population and stratified by diuretics use and eGFR. 
Variable
*
 Overall 
(N = 7531) 
Patients using diuretics 
(n = 2356) 
Patients not using diuretics 
(n = 5175) 
eGFR < 60 ml/min/1.73m
2 
(n = 2214) 
eGFR ≥ 60 ml/min/1.73m2 
(n = 5309) 
 OR  
(95% CI) 
P value OR  
(95% CI) 
P value OR  
(95% CI) 
P value OR  
(95% CI) 
P value OR  
(95% CI) 
P value 
sUA level 1.39  
(1.34–1.44) 
< 0.0001 1.32 
(1.24–1.40) 
< 0.0001 1.46 
(1.39–1.53) 
< 0.0001 1.30 
(1.22–1.38) 
< 0.0001 1.44 
(1.38–1.51) 
< 0.0001 
BMI, kg/m
2
 0.96  
(0.95–0.97) 
< 0.0001 0.95 
(0.94–0.97) 
< 0.0001 0.96 
(0.95–0.97) 
< 0.0001 0.97 
(0.95–0.99) 
0.0005 0.96 
(0.94–0.97) 
< 0.0001 
Number of CV risk factors  < 0.0001  < 0.0001  < 0.0001  < 0.0001  < 0.0001 
 1 1.00 
(–) 
 1.00  
(–) 
 1.00  
(–) 
 1.00  
(–) 
 1.00  
(–) 
 
 2 1.53  
(1.33–1.76) 
 1.73 
(1.26–2.37) 
 1.45 
(1.24–1.69) 
 1.42  
(1.09–1.85) 
 1.57 
(1.33–1.85) 
 
 3 2.19  2.45  2.10  2.07  2.22  
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(1.86–2.59) (1.74–3.44) (1.74–2.54) (1.52–2.83) (1.82–2.69) 
 4 2.47 
(2.01–3.05) 
 2.79 
(1.88–4.15) 
 2.44 
(1.89–3.16) 
 2.15 
(1.44–3.22) 
 2.59 
(2.02–3.32) 
 
 5 3.41 
(2.50–4.65) 
 4.96 
(2.94–8.35) 
 2.89 
(1.92–4.34) 
 3.90 
(2.23–6.83) 
 3.16 
(2.17–4.60) 
 
Number of comorbidities  0.0074  –  0.0011  0.4378  0.0048 
 0 1.00 
(–) 
 na
†
  1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 
 1 1.07 
(0.96–1.19) 
 na
†  1.14 
(1.01–1.29) 
 1.08 
(0.88–1.33) 
 1.07 
(0.95–1.22) 
 
 2 0.97 
(0.83–1.13) 
 na
†  1.04 
(0.86–1.26) 
 1.02 
(0.77–1.35) 
 0.94 
(0.78–1.13) 
 
 3 1.29 
(1.01–1.65) 
 na
†  1.29 
(0.92–1.82) 
 1.47 
(0.98–2.21) 
 1.25 
(0.91–1.72) 
 
 ≥ 4 1.77 
(1.22–2.55) 
 na
†  2.91 
(1.67–5.08) 
 1.22 
(0.69–2.15) 
 2.42 
(1.45–4.04) 
 
Lipid-lowering drug
‡ 
0.82 
(0.73–0.91) 
0.0002 0.85 
(0.69–1.03) 
0.0958 0.80 
(0.71–0.91) 
0.0008 0.93 
(0.75–1.14) 
0.4703 0.79 
(0.69–0.89) 
0.0002 
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Antihypertensive drug
‡
 1.27  
(1.14–1.42) 
< 0.0001 na
§
 – 1.24 
(1.09–1.41) 
0.0008 1.59 
(1.26–2.01) 
0.0001 1.21 
(1.06–1.38) 
0.0046 
Antidiabetic drug
‡
 1.07 
(0.94–1.22) 
0.3255 0.96 
(0.77–1.21) 
0.7375 1.10 
(0.94–1.29) 
0.2325 1.27 
(0.99–1.64) 
0.0632 1.02 
(0.87–1.18) 
0.8533 
BMI: body mass index, CI: confidence interval, CV: cardiovascular, eGFR: estimated glomerular filtration rate, na: not assessed, OR: odds ratio, SCORE-HDL: Systematic 
COronary Risk Evaluation algorithm including high-density lipoprotein cholesterol, sUA: serum uric acid.  
*
Each variable was adjusted for all other variables in the Table, and for study country as a potential confounder. 
†
Not significantly related to SCORE-HDL in the univariate analysis. 
‡
At least one, versus no.  
§
All patients were using antihypertensive drugs. 
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Figure legends 
Fig. 1. Mean serum sUA levels according to SCORE-HDL risk category in a) the 
overall study population, b) patients not using diuretics, c) patients using diuretics, d) 
patients with eGFR ≥ 60 ml/min/1.73 m2 and e) patients with eGFR 
< 60 ml/min/1.73 m
2
. Vertical bars denote standard deviations. P values were 
calculated using analysis of variance (ANOVA).  
eGFR: estimated glomerular filtration rate, SCORE-HDL: Systematic COronary Risk Evaluation 
algorithm including high-density lipoprotein cholesterol, sUA: serum uric acid. 
Fig. 2. Mean serum sUA levels according to SCORE risk category in a) the overall 
study population, b) patients using diuretics, c) patients not using diuretics, d) patients 
with eGFR < 60 ml/min/1.73 m
2
 and e) patients with eGFR ≥ 60 ml/min/1.73 m2. 
Vertical bars denote standard deviations. P values were calculated using analysis of 
variance (ANOVA).  
eGFR: estimated glomerular filtration rate, SCORE: Systematic COronary Risk Evaluation algorithm, 
sUA: serum uric acid. 
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Supplementary material 
Table S1. Multivariate analysis to model the association of sUA and other patient variables with SCORE in the overall population and stratified 
by diuretics use and eGFR. 
Variables Overall 
(N = 7531) 
Patients using diuretics 
(n = 2356) 
Patients not using diuretics 
(n = 5175) 
eGFR < 60 ml/min/1.73m
2 
(n = 2214) 
eGFR ≥ 60 ml/min/1.73m2 
(n = 5309) 
 OR  
(95% CI) 
P value OR  
(95% CI) 
P value OR  
(95% CI) 
P value OR  
(95% CI) 
P value OR  
(95% CI) 
P value 
sUA level 1.29 
(1.25–1.33) 
< 0.0001 1.22 
(1.15–1.28) 
< 0.0001 1.33 
(1.28–1.39) 
< 0.0001 1.23 
(1.16–1.30) 
< 0.0001 1.27 
(1.22–1.33) 
< 0.0001 
BMI, kg/m
2
 0.93 
(0.92–0.94) 
< 0.0001 0.93 
(0.92–0.94) 
< 0.0001 0.93 
(0.92–0.94) 
< 0.0001 0.94 
(0.92–0.95) 
< 0.0001 0.93 
(0.92–0.94) 
< 0.0001 
Number of CV risk factors  < 0.0001  0.3014  0.0001  0.3387  < 0.0001 
 1 1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 
 2 1.19 
(1.04–1.35) 
 1.03 
(0.78–1.37) 
 1.21 
(1.04–1.39) 
 1.18 
(0.93–1.50) 
 1.23 
(1.06–1.43) 
 
 3 1.47  1.20  1.53  1.25  1.64  
EURIKA sUA and CV risk ms R2  30 
(1.26–1.71) (0.88–1.63) (1.28–1.83) (0.95–1.66) (1.37–1.97) 
 4 1.31 
(1.08-1.59) 
 1.06 
(0.74–1.52) 
 1.41 
(1.11–1.79) 
 1.17 
(0.81–1.67) 
 1.48 
(1.17–1.86) 
 
 5 1.60 
(1.20–2.14) 
 1.45 
(0.89–2.34) 
 1.67 
(1.14–2.45) 
 1.60 
(0.96–2.67) 
 1.69 
(1.18–2.41) 
 
Number of comorbidities  < 0.0001  0.0259  < 0.0001  0.0441  0.0017 
 0 1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 1.00 
(–) 
 
 1 1.22 
(1.11–1.35) 
 1.19 
(0.99–1.42) 
 1.25 
(1.11–1.40) 
 1.18 
(0.98–1.42) 
 1.21 
(1.08–1.36) 
 
 2 1.21 
(1.05–1.40) 
 1.00 
(0.79–1.26) 
 1.35 
(1.13–1.62) 
 1.34 
(1.05–1.73) 
 1.08 
(0.90–1.28) 
 
 3 1.44 
(1.15–1.81) 
 1.45 
(1.04–2.03) 
 1.34 
(0.97–1.85) 
 1.51 
(1.04–2.20) 
 1.28 
(0.95–1.72) 
 
 ≥ 4 1.96 
(1.38–2.77) 
 1.73 
(1.08–2.79) 
 1.99 
(1.17–3.37) 
 1.54 
(0.91–2.62) 
 2.04 
(1.25–3.32) 
 
Lipid-lowering drug
† 
0.88 
(0.80–0.97) 
0.0113 0.94 
(0.78–1.13) 
0.4831 0.85 
(0.76–0.96) 
0.0102 0.93 
(0.77–1.12) 
0.4216 0.82 
0.73–0.93 
0.0015 
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Antihypertensive drug
†
 1.90 
(1.71–2.11) 
< 0.0001 na
‡
 – 1.70 
(1.51-1.91) 
< 0.0001 2.32 
(1.87–2.87) 
< 0.0001 1.68 
(1.49–1.90) 
< 0.0001 
Antidiabetic drug
†
 0.99 
(0.88–1.12) 
0.9024 0.84 
(0.68–1.04) 
0.1024 1.08 
(0.93–1.25) 
0.3425 1.14 
(0.91–1.44) 
0.2554 0.96 
(0.83–1.11) 
0.5896 
BMI: body mass index, CI: confidence interval, CV: cardiovascular, eGFR: estimated glomerular filtration rate, na: not assessed, OR: odds ratio, SCORE: Systematic 
COronary Risk Evaluation algorithm, sUA: serum uric acid.  
*
Each variable was adjusted for all other variables in the Table, and for study country as a potential confounder. 
†
At least one, versus no.  
‡
All patients were using antihypertensive drugs. 
 
 
